Skip to main content
Clinical Trials/NCT02043600
NCT02043600CompletedNot Applicable

Randomized-controlled Trial of Yoga for Ulcerative Colitis

Universität Duisburg-Essen1 site in 1 country77 target enrollmentStarted: February 1, 2014Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
77
Locations
1
Primary Endpoint
Disease-specific quality of life

Study Overview

Brief Summary

The aim of this randomized trial is to investigate the effects of a 12-week yoga intervention compared to self-care on quality of life, stress, psychological health, and physiological parameters in 77 patients with ulcerative colitis.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Ulcerative colitis (clinical, endoscopic and histological diagnosis)
  • Disease duration at least 12 months
  • Clinical remission for at least 4 weeks and less than 12 months
  • IBDQ < 170
  • Physical and mental ability to perform yoga
  • No regular practice of yoga or Pilates in the previous 12 months

Exclusion Criteria

  • Clinically active disease (CAI > 4 Rachmilewitz)
  • Complete resection of the colon
  • Acute, infectious or chronic active ulcerative colitis
  • Severe disease precluding yoga practice
  • Malignancy with a disease-free survival < 5 years except curatively treated basalioma of the skin
  • Alcohol or drug abuse
  • Pregnancy

Arms & Interventions

Yoga

Experimental

Intervention: Yoga (Behavioral)

Self-care

Active Comparator

Intervention: Self-care (Behavioral)

Outcomes

Primary Outcomes

Disease-specific quality of life

Time Frame: 3 months

Inflammatory Bowel Disease Questionnaire (IBDQ)

Secondary Outcomes

  • Body responsiveness(6 months)
  • Disease-specific quality of life(6 months)
  • Subjective stress(6 months)
  • Faecal lactoferrin(6 months)
  • Disease activity(6 months)
  • Safety(6 months)
  • Generic quality of life(6 months)
  • Body awareness(6 months)
  • C-reactive protein(6 months)
  • Faecal calprotectin(6 months)
  • Salivary cortisol level(3 months)
  • Steroid sensitivity(3 months)
  • Self-efficacy(6 months)
  • Blood sedimentation rate(6 months)
  • Faecel PMN-elastase(6 months)
  • Anxiety/depression(6 months)
  • Hemogram(6 months)
  • Positive/negative affect(6 months)
  • Andrenergic sensitivity(3 months)
  • Cholinergic sensitivity(3 months)
  • Faecel PMN-elastase(3 months)
  • Self-efficacy(3 months)
  • Faecal lactoferrin(3 months)
  • Generic quality of life(3 months)
  • Anxiety/depression(3 months)
  • Subjective stress(3 months)
  • Positive/negative affect(3 months)
  • Body awareness(3 months)
  • Body responsiveness(3 months)
  • C-reactive protein(3 months)
  • Blood sedimentation rate(3 months)
  • Faecal calprotectin(3 months)
  • Disease activity(3 months)
  • Safety(3 months)
  • Hemogram(3 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Holger Cramer

Postdoctoral Researcher

Universität Duisburg-Essen

Study Sites (1)

Loading locations...

Similar Trials